Article
Oncology
Kazuaki Okamoto, Hiroaki Nozawa, Shigenobu Emoto, Koji Murono, Kazuhito Sasaki, Soichiro Ishihara
Summary: This study aimed to investigate the tolerability and efficacy of adjuvant CAPOX therapy in elderly patients compared to young patients. The results showed that adjuvant CAPOX therapy was well-tolerated in elderly Japanese patients, and the prognosis of elderly patients with stage III CRC was similar to that of their younger counterparts. Therefore, advanced age may not be a contraindication for adjuvant chemotherapy in CRC.
Article
Cell Biology
Sha Zhou, Jianhong Peng, Liuniu Xiao, Caixia Zhou, Yujing Fang, Qingjian Ou, Jiayi Qin, Mengzhong Liu, Zhizhong Pan, Zhenlin Hou
Summary: TRIM25 is identified as an epigenetic regulator of oxaliplatin resistance in colorectal cancer patients, affecting disease-free survival and recurrence rates. Its overexpression promotes stem cell properties in CRC cells and resistance to chemotherapy. Targeting TRIM25 may be a potential strategy for managing OXA resistance in clinical practice.
CELL DEATH & DISEASE
(2021)
Article
Medicine, Research & Experimental
Minhao Yu, Hao Wang, Wei Zhao, Xiaoxiao Ge, Wei Huang, Fengjuan Lin, Wenbo Tang, Ang Li, Sailiang Liu, Rong-Kun Li, Shu-Heng Jiang, Junli Xue
Summary: This study reveals the significant role of PIPKI?? in oxaliplatin resistance and provides a key mechanism of exosomal PD-L1 in colorectal cancer with potential therapeutic implications.
Article
Oncology
Timothy J. Iveson, Alberto F. Sobrero, Takayuki Yoshino, Ioannis Souglakos, Fang-Shu Ou, Jeffrey P. Meyers, Qian Shi, Axel Grothey, Mark P. Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Niels H. Hollander, Fabio Galli, Kentaro Yamazaki, Vassilis Georgoulias, Rachel Kerr, Eiji Oki, Sara Lonardi, Andrea Harkin, Gerardo Rosati, James Paul
Summary: This study aimed to investigate the impact of reducing the duration of oxaliplatin adjuvant chemotherapy on patients with high-risk stage II colon cancer, and the results showed that noninferiority of 3-month treatment was not demonstrated.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Robert A. Nagourney, Steven Evans, Peter H. Tran, Adam J. Nagourney, Paul H. Sugarbaker
Summary: Patients with colon cancer who have received specific drug treatments are more likely to exhibit resistance to oxaliplatin, reducing the efficacy of heated intraperitoneal chemotherapy (HIPEC).
Article
Surgery
Jueun Park, HyungJoo Baik, Sang Hyun Kang, Sang Hyuk Seo, Kwang Hee Kim, Min Kyung Oh, Hong Sub Lee, Sang Heon Lee, Ki Hyang Kim, Min Sung An
Summary: This study compared the efficacy of oxaliplatin-added chemotherapy and capecitabine monotherapy in high-risk stage II/III elderly colon cancer patients, finding no significant difference in CSS and OS between the two groups. Although the oxaliplatin-added group had more stage III patients, subgroup analysis also showed no significant difference.
ASIAN JOURNAL OF SURGERY
(2022)
Article
Oncology
Kazuaki Okamoto, Hiroaki Nozawa, Shigenobu Emoto, Koji Murono, Kazuhito Sasaki, Soichiro Ishihara
Summary: The current study aimed to investigate whether statins could prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients with colorectal cancer (CRC) receiving adjuvant CAPOX therapy. The results showed that the efficacy of statins to attenuate OIPN during adjuvant CAPOX therapy was not apparent in the current study.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Katie Watts, Christopher Wills, Ayman Madi, Claire Palles, Timothy S. Maughan, Richard Kaplan, Nada A. Al-Tassan, Rachel Kerr, David Kerr, Victoria Gray, Hannah West, Richard S. Houlston, Valentina Escott-Price, Jeremy P. Cheadle
Summary: This study identified associations between MROH5 and neutropenia in colorectal cancer patients treated with oxaliplatin and fluoropyrimidine chemotherapy, as well as validated other potential biomarkers for personalized treatment. Despite extensive genome-wide analyses, common variants with modest effects associated with toxicities were lacking.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Robert B. Hines, Christopher Schoborg, Timothy Sumner, Xiang Zhu, Elizabeth A. Elgin, Shunpu Zhang
Summary: The purpose of this study was to evaluate whether preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. The results showed that no therapies reduced the rate of OIPN diagnosis.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Pharmacology & Pharmacy
Chengzhi Huang, Minjia Wang, Junjiang Wang, Deqing Wu, Yuan Gao, Kaihong Huang, Xueqing Yao
Summary: The study revealed that overexpression of MGP in colorectal cancer may contribute to oxaliplatin resistance and be associated with cancer stage and patient prognosis. Inhibition of MGP expression can increase sensitivity of CRC cells to OXA, potentially reversing resistance and reducing tumor growth.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Polymer Science
Naser Rasouli, Daryoush Shahbazi-Gahrouei, Simin Hematti, Behzad Baradaran, Roya Salehi, Jaleh Varshosaz, Abbas Jafarizad
Summary: This study investigates the potential of oxaliplatin-loaded iodine nanoparticles in the treatment of colorectal cancer. The results show that these nanoparticles can enhance the radiosensitivity and promote apoptosis of cancer cells. Additionally, the nanoparticles have no impact on cell cycle development. Therefore, iodine nanoparticles may be used as a treatment for colorectal cancer.
Article
Oncology
Hanla A. Park, Dominic Edelmann, Federico Canzian, Petra Seibold, Tabitha A. Harrison, Xinwei Hua, Qian Shi, Allison Silverman, Axel Benner, Angelica Macauda, Martin Schneider, Richard M. Goldberg, Steven R. Alberts, Michael Hoffmeister, Hermann Brenner, Andrew T. Chan, Ulrike Peters, Polly A. Newcomb, Jenny Chang-Claude
Summary: We conducted the first large-scale genome-wide association study to identify genetic variants that can predict the prognosis of colorectal cancer patients undergoing different chemotherapy treatments. Our analysis revealed specific loci associated with overall survival in stage III colon cancer patients and metastatic colorectal cancer patients. These findings may have significant implications for personalized treatment and improved clinical outcomes.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Pharmacology & Pharmacy
Fang Cheng, Ruoqi Zhang, Chen Sun, Qian Ran, Cuihan Zhang, Changhong Shen, Ziqing Yao, Miao Wang, Lin Song, Cheng Peng
Summary: Oxaliplatin-based chemotherapy is a standard treatment for colorectal cancer but can cause severe peripheral neurotoxicity. This article explores the mechanisms, therapeutic strategies, and pharmacokinetics of different methods of oxaliplatin administration to counteract this toxicity. Strategies include combination with chemoprotectants, timing modulation of infusion, dose reduction, reintroduction of oxaliplatin, and topical administration.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Camille Julio, Stephane Benoist, Marc-Antoine Allard, Francis Navarro, Patrick Pessaux, Antonio Sa Cunha, Antoine Brouquet
Summary: The background outcome of patients with resectable metachronous colorectal liver metastases after adjuvant oxaliplatin-based chemotherapy for colorectal cancer is not well defined, and the value of preoperative chemotherapy is controversial.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Keyla Vargas-Roman, Maria Isabel Tovar-Galvez, Antonio Linan-Gonzalez, Guillermo Arturo Canadas de la Fuente, Emilia Inmaculada de la Fuente-Solana, Lourdes Diaz-Rodriguez
Summary: This article summarizes the impact of coping strategies on the quality of life of colorectal cancer patients. The results suggest that coping strategies can help patients adapt and overcome the stress caused by the disease. For elderly patients, learning coping strategies may improve their quality of life after cancer diagnosis. However, more research is needed to validate this hypothesis, as there is limited randomized evidence available.
Article
Oncology
Heather Payne, Angus Robinson, Bernard Rappe, Serena Hilman, Ugo De Giorgi, Steven Joniau, Roberto Bordonaro, Stephane Mallick, Louis-Marie Dourthe, Moises Mira Flores, Josep Guma, Benoit Baron, Aurea Duran, Alessandra Pranzo, Alexis Serikoff, David Mott, Mike Herdman, Marco Pavesi, Maria De Santis
Summary: In a real-world European setting, the study confirmed the efficacy and safety of enzalutamide in mCRPC patients, with outcomes consistent with clinical trial results. Patients showed improvements in health-related quality of life and pain status while experiencing similar rates of treatment-emergent adverse events across cohorts.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Gerardo Rosati, Domenico Corsi, Antonio Avallone, Silvia Brugnatelli, Emanuela Dell'Aquila, Marika Cinausero, Giuseppe Aprile, Giuseppe Cicero, Chiara Carlomagno, Alfredo Colombo, Stefania Rapisardi, Carmine Pinto, Giorgio Reggiardo, Domenico Bilancia
Summary: This study demonstrates that vulnerable older patients can best tolerate chemotherapy when combined with anti-EGFR antibodies with an appropriate design, including reduced doses.
JOURNAL OF GERIATRIC ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Giorgio Minotti, Emanuela Salvatorelli, Giorgio Reggiardo, Fabio Mangiacapra, Massimiliano Camilli, Pierantonio Menna
Summary: Diastolic dysfunction (DD) may occur before heart failure (HF) in cancer patients treated with chemotherapy. By analyzing data from patients treated with anthracyclines, it was found that the risk of DD is lower than the risk of HF and the levels of B-type natriuretic peptide (BNP) can help identify patients with high or low risk of DD.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2022)
Letter
Oncology
Giorgio Minotti, Giorgio Reggiardo, Massimiliano Camilli, Emanuela Salvatorelli, Pierantonio Menna
JACC: CARDIOONCOLOGY
(2022)
Review
Oncology
Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Roberta Galdiero, Nicola Maggialetti, Lucrezia Silvestro, Mario De Bellis, Elena Di Girolamo, Giulia Grazzini, Giuditta Chiti, Maria Chiara Brunese, Andrea Belli, Renato Patrone, Raffaele Palaia, Antonio Avallone, Antonella Petrillo, Francesco Izzo
Summary: Pancreatic cancer is one of the deadliest cancers, and late diagnosis is the main reason for its high mortality rate. Surgical resection is the only curative treatment, so early diagnosis is crucial for improving survival. Therefore, it is appropriate to stratify patients based on familial and genetic risk and develop screening protocols using minimally invasive diagnostic tools.
Article
Oncology
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, Laura Arenare, Carmela Pisano, Davide Lombardi, Ugo De Giorgi, Claudia Andreetta, Saverio Cinieri, Carmine De Angelis, Domenico Priolo, Claudia Casanova, Marta Rosati, Filippo Greco, Elena Zafarana, Ilaria Schiavetto, Serafina Mammoliti, Sabrina Chiara Cecere, Vanda Salutari, Simona Scalone, Alberto Farolfi, Marilena Di Napoli, Domenica Lorusso, Piera Gargiulo, Daniela Califano, Daniela Russo, Anna Spina, Rossella De Cecio, Paolo Chiodini, Francesco Perrone
Summary: This study compared carboplatin and paclitaxel with avelumab plus carboplatin and paclitaxel as first-line treatment in patients with advanced or recurrent endometrial cancer. The addition of avelumab showed potential for improving progression-free survival, but further investigation is needed.
Article
Clinical Neurology
Giorgio Reggiardo, Maria Lo Giudice, Stefania Lalli, Gilberto Rinaldi, Alberto Albanese
Summary: Recent phase II pilot clinical trials showed that TUDCA may slow functional decline and increase survival in ALS patients. A multivariate analysis of the original TUDCA cohort demonstrated significant differences in the decline rate and survival time between the active treatment and placebo groups. These findings further support the disease-modifying effect of TUDCA and raise questions about combining it with sodium phenylbutyrate.
FRONTIERS IN NEUROLOGY
(2023)
Review
Medicine, General & Internal
Michele Montrone, Gerardo Rosati, Vito Longo, Annamaria Catino, Raffaella Massafra, Annalisa Nardone, Francesco Pesola, Elisabetta Sara Montagna, Ilaria Marech, Pamela Pizzutilo, Domenico Galetta
Summary: Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 80% of cases. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic and early-stage NSCLC. However, the elderly face challenges in treatment due to comorbidities and reduced organ function. Despite less toxicity compared to chemotherapy, ICIs may be less effective in patients older than 75, possibly due to immunosenescence. This review explores the role of immunotherapy in elderly NSCLC patients, considering the biological aspects of immunosenescence.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Davide Ciardiello, Stefania Napolitano, Vincenzo Famiglietti, Lucia Esposito, Vincenzo De Falco, Alessandra Di Liello, Antonio Avallone, Evaristo Maiello, Filippo Pietrantonio, Chiara Cremolini, Maria Giulia Zampino, Nicola Fazio, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Giulia Martini
Summary: Rechallenge with EGFR inhibitors is a promising strategy in refractory RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients. The presence of plasma ctDNA RAS/BRAF mutations at pretreatment liquid biopsy analysis was not associated with the length of anti-EGFR drug-free interval. Liquid biopsy can be used to select suitable patients for EGFR inhibitor rechallenge.
Article
Oncology
Thierry Andre, Filippo Pietrantonio, Antonio Avallone, Mahmut Gumus, Lucjan Wyrwicz, Jong Gwang Kim, Suayib Yalcin, Mariusz Kwiatkowski, Sara Lonardi, Jakub Zolnierek, Amos Odeleye-Ajakaye, Pierre Leconte, David Fogelman, Tae Won Kim
Summary: Robust clinical activity has been observed with pembrolizumab in treating MSI-H/dMMR mCRC. However, there is still room for improvement in terms of response rate and progression-free survival. The KEYSTEP-008 trial aims to evaluate the efficacy and safety of pembrolizumab-based combination therapy compared with monotherapy in chemotherapy-refractory or previously untreated MSI-H/dMMR mCRC. Rating: 9/10
Article
Health Care Sciences & Services
Marco Cascella, Emanuela Racca, Anna Nappi, Sergio Coluccia, Sabatino Maione, Livio Luongo, Francesca Guida, Antonio Avallone, Arturo Cuomo
Summary: This study developed a data-driven prediction model for identifying cancer patients at a higher risk for unplanned hospital readmissions (HRAs). The results showed that nutritional support and radiotherapy were directly related to HRAs, while breakthrough cancer pain (BTcP) did not significantly affect readmissions.
Review
Biochemistry & Molecular Biology
Giuseppe Gattuso, Salvatore Crimi, Alessandro Lavoro, Roberta Rizzo, Giorgia Musumarra, Simona Gallo, Flavia Facciponte, Sabrina Paratore, Angela Russo, Roberto Bordonaro, Gaetano Isola, Alberto Bianchi, Massimo Libra, Luca Falzone
Summary: Liquid biopsy has emerged as a promising minimally invasive tool for the early detection and personalized treatment of oral cancer, by detecting circulating biomarkers. However, further studies are needed to clarify its clinical impact.
Article
Health Policy & Services
Roberta Spatuzzi, Maria Velia Giulietti, Francesca Romito, Giorgio Reggiardo, Carmela Genovese, Michele Passarella, Letizia Raucci, Marcello Ricciuti, Fabiana Merico, Gerardo Rosati, Luigi Attademo, Anna Vespa
Summary: This study aimed to assess the burden experienced by older family caregivers who care for cancer patients at the end of their lives, and compare the differences according to gender. The results showed that older female caregivers are at a higher risk of burden and worse physical health compared to male caregivers. This highlights the need for further research on the role of gender differences in the experience of caregiving among older individuals in modern palliative care.
PALLIATIVE & SUPPORTIVE CARE
(2022)
Article
Social Work
Roberta Spatuzzi, Anna Vespa, Paolo Fabbietti, Marcello Ricciuti, Gerardo Rosati, Lorella Guariniello, Maria Antonietta Flavia Verrastro, Luigi Attademo, Maria Velia Giulietti
Summary: A new reality is being observed around the world as the population ages: family caregivers, who are themselves older adults helping their ill older relatives. This study assessed the burden of older family caregivers assisting older patients with dementia or cancer at the end-of-life. The findings suggest that elderly individuals helping those with Alzheimer's disease are at a higher risk of experiencing emotional burden compared to cancer caregivers.
JOURNAL OF SOCIAL WORK IN END-OF-LIFE & PALLIATIVE CARE
(2022)
